4BASEBIO UK SOCIETAS Total Liabilities
4BASEBIO UK SOCIETAS total liabilities. Based on the latest financial reports, 4BASEBIO UK SOCIETAS (4BB) has total liabilities worth GBX19.44 Million GBX (≈ $2.37K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 4BB financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of 4BASEBIO UK SOCIETAS (2019–2025)
Total liabilities of 4BASEBIO UK SOCIETAS from 2019 to 2025. This chart illustrates how 4BASEBIO UK SOCIETAS's total liabilities have evolved over time, based on quarterly financial data.
4BASEBIO UK SOCIETAS Competitors by Total Liabilities
The table below lists competitors of 4BASEBIO UK SOCIETAS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Anpario Plc
LSE:ANP
|
UK | GBX9.53 Million |
|
Quintegra Solutions Limited
NSE:QUINTEGRA
|
India | Rs142.76 Million |
|
Fram Skandinavien AB Series B
ST:FRAM-B
|
Sweden | Skr19.35 Million |
|
Sarawak Cable Bhd
KLSE:5170
|
Malaysia | RM466.66 Million |
|
Ridgestone Mining Inc
V:RMI
|
Canada | CA$779.37K |
|
Rimo International Lestari Tbk PT
JK:RIMO
|
Indonesia | Rp569.64 Billion |
|
WELLFIELD TECHNOLOG. INC.
F:K8D
|
Germany | €35.06 Million |
|
Biora Therapeutics Inc
NASDAQ:BIOR
|
USA | $121.13 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down 4BASEBIO UK SOCIETAS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 4BB total assets.
Liquidity & Leverage Metrics
4BASEBIO UK SOCIETAS Total Liabilities Ratios Explained
4BASEBIO UK SOCIETAS total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.92 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 4BASEBIO UK SOCIETAS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 4BASEBIO UK SOCIETAS (2019–2025)
The table below shows the annual total liabilities of 4BASEBIO UK SOCIETAS from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | GBX19.44 Million ≈ $2.37K |
+5.95% |
| 2024-12-31 | GBX18.35 Million ≈ $2.23K |
+47.79% |
| 2023-12-31 | GBX12.41 Million ≈ $1.51K |
+171.70% |
| 2022-12-31 | GBX4.57 Million ≈ $555.92 |
+51.95% |
| 2021-12-31 | GBX3.01 Million ≈ $365.86 |
+27.90% |
| 2020-12-31 | GBX2.35 Million ≈ $286.05 |
-22.79% |
| 2019-12-31 | GBX3.04 Million ≈ $370.49 |
-- |
About 4BASEBIO UK SOCIETAS
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for u… Read more